Table 3 Results of Meta-Analysis Evaluating the Association Between Prescriber and Patient Characteristics and Warfarin Use
Characteristic | N Studies | Pooled OR (95%CI) | I2 | Qp | Egger's p |
|---|---|---|---|---|---|
Advancing (dichotomous) age* | 11 | 0.57 (0.39-0.82) | 79% | < 0.0001 | 0.40 |
Age per 10 year increase | 4 | 0.78 (0.68-0.90) | 70% | 0.02 | 0.20 |
Alcohol or drug abuse | 2 | 0.62 (0.40-0.96) | NA | 0.72 | NA |
Coronary artery disease | 3 | 1.08 (0.82-1.42) | 39% | 0.20 | NA |
Congestive heart failure | 8 | 1.36 (1.18-1.57) | 84% | < 0.0001 | 0.60 |
Contraindications to warfarin | 3 | 0.81 (0.69-0.96) | 0% | 0.58 | NA |
Cerebral vascular accident | 10 | 1.58 (1.15-2.18) | 93% | < 0.0001 | 0.84 |
Dementia | 3 | 0.32 (0.14-0.75) | 78% | 0.01 | NA |
Diabetes | 2 | 1.11 (0.97-1.26) | NA | 0.52 | NA |
Falls | 4 | 0.60 (0.43-0.85) | 83% | 0.0006 | 0.25 |
Gastrointestinal bleeding | 3 | 0.47 (0.40-0.55) | 0% | 0.51 | NA |
History of bleeding | 3 | 0.47 (0.21-1.03) | 80% | 0.007 | NA |
Hepatic impairment | 2 | 0.59 (0.50-0.70) | NA | > 0.99 | NA |
Hypertension | 5 | 1.34 (0.99-1.81) | 91% | < 0.0001 | 0.48 |
Intracranial bleeding | 3 | 0.39 (0.28-0.55) | 2% | 0.36 | NA |
Male gender | 11 | 1.12 (1.04-1.21) | 58% | 0.008 | 0.17 |
Perceived barriers to compliance | 2 | 0.87 (0.76-0.99) | NA | 0.32 | NA |
Renal impairment | 6 | 0.69 (0.60-0.80) | 70% | 0.005 | 0.40 |